+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients



Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients



Transplantation 96(6): 573-578



Limited data exist regarding echinocandins as antifungal prophylaxis in liver transplant recipients. The efficacy and safety of targeted prophylaxis with micafungin or amphotericin B lipid complex (ABLC) was assessed in a sequential cohort of high-risk patients (posttransplantation dialysis, retransplantation, or reoperation) and compared with those without high risk who did not receive prophylaxis. Outcomes were assessed at 90 days. Micafungin versus ABLC recipients were older (P=0.0065) and more likely to have hepatocellular carcinoma (P=0.025). High-risks, that is, dialysis (55.6% vs. 79.2%), retransplantation (5.6% vs. 12.5%), and reoperation (38.9% vs. 20.8%) did not differ between the two groups. Invasive fungal infections developed in 11.1% (2 of 18) of micafungin recipients, 8.3% (2 of 24) of ABLC recipients, and 3% (7 of 234) of patients without high risks (P=0.12). In nondialyzed patients, ABLC versus micafungin recipients had significantly higher serum creatinine on day 14 (P=0.04). However, renal and hepatic function, rejection, graft loss, and mortality did not differ for the two groups on day 90. Targeted prophylaxis with micafungin or ABLC decreased the risk of mycoses in high-risk recipients compared with that in low-risk recipients. Compared with ABLC, however, micafungin appeared to be associated with lower early-renal dysfunction and no additional risk of hepatic dysfunction.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054362752

Download citation: RISBibTeXText

PMID: 23842191

DOI: 10.1097/tp.0b013e31829d674f


Related references

Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. Journal of Antimicrobial ChemoTherapy 52(5): 813-819, 2003

Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clinical Infectious Diseases 60(7): 997-1006, 2016

Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 315, 2002

Preemptive prophylaxis with lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring dialysis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 381, 2000

Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clinical Transplantation 14(4 Pt 1): 329-339, 2000

Amphotericin B lipid complex in the treatment of invasive fungal infections in liver transplant patients. Transplantation Proceedings 29(6): 2670-2674, 1997

Preemptive Prophylaxis With A Lipid Preparation Of Amphotericin B For Invasive Fungal Infections In Liver Transplant Recipients Requiring Renal Replacement Therapy1. Transplantation 71(7): 910-913, 2001

Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 71(7): 910-913, 2001

Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clinical Therapeutics 29(9): 1980-1986, 2007

Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. American Journal of Transplantation 14(12): 2758-2764, 2015

Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. Journal of Infection 73(5): 496-505, 2016

Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. Transplantation 94(3): 302-308, 2012

Liposomal Amphotericin B Prevents Invasive Fungal Infections In Liver Transplant Recipients. Transplantation 59(1): 45-50, 1995

Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 87(3): 424-435, 2009

Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. Clinical Infectious Diseases 37(1): 17-25, 2003